决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Claudins in Cancer: A Current and Future Therapeutic Target.
Claudins in Cancer: A Current and Future Therapeutic Target.
Claudin 是一个包含 27 种蛋白的家族,在紧密连接的形成中发挥重要作用。
Claudin 是由 27 种蛋白组成的家族,在紧密连接形成中发挥重要作用。Claudin 还参与离子交换、细胞运动和上皮间质转化;后者对癌症侵袭和转移尤为重要。研究者已探索靶向 claudin 以改善癌症结局。近期证据显示,胃食管结合部癌患者接受抗 claudin 18.2 单克隆抗体联合化疗可改善结局。目前正在研究靶向 claudin 18 的CAR-T 细胞。本综述讨论 claudin 的主要功能、其在正常及癌变组织中的分布,以及其对癌症转移的影响,特别关注靶向 claudin 改善癌症结局的治疗策略。
Claudins are a family of 27 proteins that have an important role in the formation of tight junctions. They also have an important function in ion exchange, cell mobility, and the epithelial-to-mesenchymal transition, the latter being very important in cancer invasion and metastasis. Therapeutic targeting of claudins has been investigated to improve cancer outcomes. Recent evidence shows improved outcomes when combining monoclonal antibodies against claudin 18.2 with chemotherapy for patients with gastroesophageal junction cancer. Currently, chimeric antigen receptor T-cells targeting claudin 18 are under investigation. In this review, we will discuss the major functions of claudins, their distribution in the normal as well as cancerous tissues, and their effect in cancer metastasis, with a special focus on the therapeutic targeting of claudins to improve cancer outcomes.
MEMBER ACCOUNT
登录成功会直接打开下一页。